Back to School: How biopharma can reboot drug development. Access exclusive analysis here

TheraeCIM hR3 nimotuzumab: Completed Phase III enrollment

Oncoscience completed enrollment of 40 patients in an international Phase III

Read the full 111 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE